Publications by authors named "Sigrun Greil-Ressler"
Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Simon P Gampenrieder Magdalena Pircher Christian Fesl Gabriel Rinnerthaler Brigitte Mlineritsch Sigrun Greil-Ressler
Breast Care (Basel)
April 2022
Background: Associations between height, cancer risk and worse outcome have been reported for several cancers including breast cancer. We hypothesized that in breast cancer clinical trials, tall women should be overrepresented and might have worse prognosis.
Methods: Data of 4,935 women, included from 1990 to 2010 in 5 trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG), were analyzed retrospectively.
Article Synopsis
- A phase 3 trial evaluated the effectiveness of extending adjuvant aromatase inhibitor therapy (anastrozole) from 2 to 5 additional years in postmenopausal women with hormone-receptor-positive breast cancer after 5 years of prior treatment.
- The study found no significant difference in disease-free survival between the two duration groups, with a similar number of disease progression or death cases in both.
- However, the 5-year group had a higher risk of clinical bone fractures compared to the 2-year group, indicating that longer hormone therapy may not be beneficial and could pose additional risks.
Article Synopsis
- Acute myeloid leukemia (AML) primarily affects older adults, and treatment options are limited after hypomethylating agents (HMA) fail, leading to poor survival rates.
- A case series in Salzburg, Austria, treated seven patients with secondary AML (sAML) who were not suitable for intensive chemotherapy and had previously not responded to HMA with the BCL-2 inhibitor venetoclax.
- The results showed that two patients achieved complete remission, with significant overall survival differences between responders (average 364 days) and non-responders (average 24 days), indicating that venetoclax is a promising option for treatment after HMA failure.
Article Synopsis
- The study explored how co-medications affect plasma levels of curcumin and tetrahydrocurcumin in cancer patients, also comparing their pharmacokinetics to healthy individuals receiving Lipocurc™ (liposomal curcumin).
- Findings revealed that certain co-medications, particularly those targeting the renin-angiotensin system like Lisinopril, Ramipril, and Valsartan, significantly increased curcumin and THC plasma levels in patients, while infusion rate also influenced these levels.
- The research concluded that both the presence of co-medications and the health status of patients play a role in how curcumin properties are absorbed and eliminated in the body
Article Synopsis
- The study aimed to assess the safety and tolerability of increasing doses of liposomal curcumin in patients with metastatic cancer, while also exploring its anti-tumor effects and pharmacokinetics.
- Conducted in a phase I trial, 32 patients received weekly intravenous infusions of liposomal curcumin over 8 weeks, starting at 100 mg/m and increasing to 300 mg/m.
- Findings showed that 300 mg/m over 6 hours was the highest tolerated dose, with some patients experiencing minor adverse effects; no significant anti-tumor activity was observed, but two patients showed transient clinical benefits.
Article Synopsis
- - Primary resistant Hodgkin lymphoma is an aggressive cancer that has limited treatment options and generally poor survival rates, with a notable dependence on the tumor microenvironment and PD-L1 expression.
- - A specific patient, who did not respond to five different chemotherapy treatments, showed a remarkable response to an anti-PD1 monoclonal antibody (mab) and sustained responses to additional therapies like ipilimumab and ruxolitinib for two years.
- - Genomic analysis of the patient revealed seven mutations, including six novel alterations, with three being actionable; one of these mutations was found to be hereditary, indicating the evolving nature of genetic changes in the cancer over time.